SCHEMBL17832298

SCHEMBL17832298

Cc1nc(F)c(-c2ccc(N)cc2)[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ HPGD P15428 4/20 0.42
▸ MAPK14 Q16539 5/20 0.41
▸ GCGR P47871 2/20 0.41
▸ MAPK13 O15264 1/20 0.41
▸ ALOX5 P09917 1/20 0.41
▸ MAPK12 P53778 1/20 0.41
▸ MAPK11 Q15759 1/20 0.41
▸ ALDH1A1 P00352 6/20 0.40
▸ NPC1 O15118 4/20 0.40
▸ MAPT P10636 4/20 0.40
▸ RAB9A P51151 4/20 0.40
▸ GFER P55789 4/20 0.40
▸ POLB P06746 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ GLA P06280 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ RXFP1 Q9HBX9 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24427332 0.80 TLR9 (0.42) KDM4ESMN1; SMN2HPGDALDH1A1NPC1
SCHEMBL24427598 0.78 KDM4E (0.42) KDM4ESMN1; SMN2HPGDMAPK14GCGR
SCHEMBL24427244 0.75 MPL (0.40) SMN1; SMN2ACHEPARP1
SCHEMBL24427514 0.74 PDPK1 (0.52) —
SCHEMBL24427480 0.73 MAPK14 (0.36) MAPK14ALOX5
SCHEMBL24428023 0.72 CREBBP (0.37) KDM4EHPGDALDH1A1MAPTPOLB
SCHEMBL24427251 0.72 MAPK14 (0.39) KDM4ESMN1; SMN2HPGDMAPK14ALDH1A1
SCHEMBL17832296 0.71 NOS3 (0.34) KDM4ESMN1; SMN2HPGDPOLBADORA2A
SCHEMBL24427894 0.70 RPS6KA3 (0.49) KDM4ESMN1; SMN2HPGDMAPK14GCGR
SCHEMBL24427783 0.70 KDM4E (0.35) KDM4ESMN1; SMN2HPGDPOLBPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230138003-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2023-05-04 — — US disclosed
US-11566027-B2 Dihydroindolizinone derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2023-01-31 — — US disclosed
US-20210009586-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2021-01-14 — — US disclosed
US-10815233-B2 Dihydroindolizinone derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2020-10-27 — — US disclosed
EP-3702357-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2020-09-02 — — EP disclosed
US-20200140435-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2020-05-07 — — US disclosed
US-10550119-B2 Dihydroindolizinone derivative ONO PHARMACEUTICAL CO., LTD. (JP) 2020-02-04 — — US disclosed
US-20190352304-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2019-11-21 — — US disclosed
US-20170349580-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2017-12-07 — — US disclosed
EP-3231803-A1 DIHYDROINDOLIZINONE DERIVATIVE ONO Pharmaceutical Co., Ltd. (JP) 2017-10-18 — — EP disclosed
WO-2016093285-A1 DIHYDROINDOLIZINONE DERIVATIVE 小野薬品工業株式会社 2016-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349580-A1 DIHYDROINDOLIZINONE DERIVATIVE CYP2C19, CYP4A22, CYP4A11 KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885
US-10815233-B2 Dihydroindolizinone derivative CYP2C19, CYP4A22, CYP4A11 KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885
US-20190352304-A1 DIHYDROINDOLIZINONE DERIVATIVE CYP2C19, CYP4A22, CYP4A11 KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885
US-20200140435-A1 DIHYDROINDOLIZINONE DERIVATIVE CYP2C19, CYP4A22, CYP4A11 KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885
US-20230138003-A1 DIHYDROINDOLIZINONE DERIVATIVE TFPI, F2, TFPI2 KDM4E 414/4885SMN1; SMN2 1935/4885HPGD 11/4885
US-20210009586-A1 DIHYDROINDOLIZINONE DERIVATIVE CYP2C19, CYP4A22, CYP4A11 KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885
US-11566027-B2 Dihydroindolizinone derivative CYP2C19, CYP4A22, CYP4A11 KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885
US-10550119-B2 Dihydroindolizinone derivative CYP2C19, CYP4A22, CYP4A11 KDM4E 420/4885SMN1; SMN2 2258/4885HPGD 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback